Recent from talks
Main milestones
Post-Polio Research and Salk Institute Timeline
Honors, Awards and Recognition Timeline
Controversies Timeline
Personal Life and Relationships Timeline
Early Life and Education Timeline
Polio Vaccine Development Timeline
Nothing was collected or created yet.
Jonas Salk
View on Wikipedia
Jonas Edward Salk (/sɔːlk/; born Jonas Salk; October 28, 1914 – June 23, 1995) was an American virologist and medical researcher who developed one of the first successful polio vaccines. He was born in New York City and attended the City College of New York and New York University School of Medicine.[2]
Key Information
In 1947, Salk accepted a professorship at the University of Pittsburgh School of Medicine, where he undertook a project beginning in 1948 to determine the number of different types of poliovirus. For the next seven years, Salk devoted himself to developing a vaccine against polio.
Salk was immediately hailed as a "miracle worker" when the vaccine's success was first made public in April 1955, and chose to not patent the vaccine or seek any profit from it in order to maximize its global distribution.[2] The National Foundation for Infantile Paralysis and the University of Pittsburgh looked into patenting the vaccine, but since Salk's techniques were not novel, their patent attorney said, "If there were any patentable novelty to be found in this phase it would lie within an extremely narrow scope and would be of doubtful value."[3][4] An immediate rush to vaccinate began in the United States and around the world. Many countries began polio immunization campaigns using Salk's vaccine, including Canada, Sweden, Denmark, Norway, West Germany, the Netherlands, Switzerland, and Belgium. By 1959, the Salk vaccine had reached about 90 countries.[5] An attenuated live oral polio vaccine was developed by Albert Sabin, coming into commercial use in 1961. Less than 25 years after the release of Salk's vaccine, domestic transmission of polio had been eliminated in the United States.[6]
In 1963, Salk founded the Salk Institute for Biological Studies in La Jolla, California, which is today a center for medical and scientific research. He continued to conduct research and publish books in his later years, focusing in his last years on the search for a vaccine against HIV. Salk campaigned vigorously for mandatory vaccination throughout the rest of his life, calling the universal vaccination of children against disease a "moral commitment".[7] Salk's personal papers are today stored in Geisel Library at the University of California, San Diego.[8][9]
Early life and education
[edit]Jonas Salk was born on October 28, 1914, in New York City to Daniel and Dora (née Press) Salk. His parents were Jewish; Daniel was born in New Jersey to immigrant parents while Dora was born in Minsk and emigrated to the United States when she was 12.[10][11] Salk's parents did not receive extensive formal education.[12] He had two younger brothers, Herman and Lee, a child psychologist.[13] The family moved from East Harlem to 853 Elsmere Place in the Bronx,[14] with some time spent in Queens at 439 Beach 69th Street, Arverne.[15]
At age 13, Salk entered Townsend Harris Hall Prep School, a public school for intellectually gifted students. Named after the founder of City College of New York (CCNY), it was "a launching pad for the talented sons of immigrant parents who lacked the money—and pedigree—to attend a top private school", according to David Oshinsky, his biographer. In high school, "he was known as a perfectionist...who read everything he could lay his hands on," according to one of his fellow students.[16] Students had to cram a four-year curriculum into just three years. As a result, most dropped out or flunked out, despite the school's motto "study, study, study." However, of the students who graduated, most had the grades to enroll in CCNY, then noted for being a highly competitive college.[17]: 96
Education
[edit]Salk enrolled in CCNY, where he earned a Bachelor of Science degree in chemistry in 1934.[18] Oshinsky writes that "for working-class immigrant families, City College represented the apex of public higher education. Getting in was tough, but tuition was free. Competition was intense, but the rules were fairly applied. No one got an advantage based on an accident of birth."[17]
At his mother's urging, he put aside aspirations of becoming a lawyer and instead concentrated on classes necessary for admission to medical school. However, according to Oshinsky, the facilities at City College were "barely second rate." There were no research laboratories. The library was inadequate. The faculty contained few noted scholars. "What made the place special," he writes, "was the student body that had fought so hard to get there...driven by their parents.... From these ranks, of the 1930s and 1940s, emerged a wealth of intellectual talent, including more Nobel Prize winners—eight—and PhD recipients than any other public college except the University of California at Berkeley." Salk entered CCNY at the age of 15, a "common age for a freshman who had skipped multiple grades along the way."[17]: 98
As a child, Salk did not show any interest in medicine or science in general. He said in an interview with the Academy of Achievement,[19] "As a child I was not interested in science. I was merely interested in things human, the human side of nature, if you like, and I continue to be interested in that."
Medical school
[edit]After graduating from City College of New York, Salk enrolled in New York University School of Medicine. According to Oshinsky, NYU based its modest reputation on famous alumni, such as Walter Reed, who helped conquer yellow fever. Tuition was "comparatively low, better still, it did not discriminate against Jews...while most of the surrounding medical schools—Cornell, Columbia, University of Pennsylvania, and Yale—had rigid quotas in place." Yale, for example, accepted 76 applicants in 1935 out of a pool of 501. Although 200 of the applicants were Jewish, only five got in.[17]: 98 During his years at New York University Medical School, Salk worked as a laboratory technician during the school year and as a camp counselor in the summer.[18]
During Salk's medical studies, he stood out from his peers, according to Bookchin, "not just because of his continued academic prowess—he was Alpha Omega Alpha, the Phi Beta Kappa Society of medical education—but because he had decided he did not want to practice medicine." Instead, he became absorbed in research, even taking a year off to study biochemistry. He later focused more of his studies on bacteriology, which had replaced medicine as his primary interest. He said his desire was to help humankind in general rather than single patients.[16] "It was the laboratory work, in particular, that gave new direction to his life."[17]
Salk has said, "My intention was to go to medical school, and then become a medical scientist. I did not intend to practice medicine, although in medical school, and in my internship, I did all the things that were necessary to qualify me in that regard. I had opportunities along the way to drop the idea of medicine and go into science. At one point at the end of my first year of medical school, I received an opportunity to spend a year in research and teaching in biochemistry, which I did. And at the end of that year, I was told that I could, if I wished, switch and get a Ph.D. in biochemistry, but my preference was to stay with medicine. And, I believe that this is all linked to my original ambition, or desire, which was to be of some help to humankind, so to speak, in a larger sense than just on a one-to-one basis."[20]
In his last year of medical school, Salk said, "I had an opportunity to spend time in elective periods in my last year in medical school, in a laboratory that was involved in studies on influenza. The influenza virus had just been discovered about a few years before that. And, I saw the opportunity at that time to test the question as to whether we could destroy the virus infectivity and still immunize. And so, by carefully designed experiments, we found it was possible to do so."[21]
Postgraduate research and early laboratory work
[edit]In 1941, during his postgraduate work in virology, Salk chose a two-month elective to work in the Thomas Francis' laboratory at the University of Michigan. Francis had recently joined the faculty of the medical school after working for the Rockefeller Foundation, where he had discovered the type B influenza virus. According to Bookchin, "the two-month stint in Francis's lab was Salk's first introduction to the world of virology—and he was hooked."[16]: 25 After graduating from medical school, Salk began his residency at New York's prestigious Mount Sinai Hospital, where he again worked in Francis's laboratory.[17] Salk then worked at the University of Michigan School of Public Health with Francis, on an army-commissioned project in Michigan to develop an influenza vaccine. He and Francis eventually perfected a vaccine that was soon widely used at army bases, where Salk discovered and isolated one of the strains of influenza that was included in the final vaccine.[16]: 26
Polio research
[edit]
In 1947, Salk became ambitious for his own lab and was granted one at the University of Pittsburgh School of Medicine, but the lab was smaller than he had hoped, and he found the rules imposed by the university restrictive.[22]
In 1948, Harry Weaver, the director of research at the National Foundation for Infantile Paralysis, contacted Salk. He asked Salk to find out if there were more types of polio than the three then known and offered additional space, equipment and researchers. For the first year, he gathered supplies and researchers, including Julius Youngner, Byron Bennett, L. James Lewis, Elsie N. Ward, and secretary Lorraine Friedman who joined Salk's team as well.[23][24] As time went on, Salk began securing grants from the Mellon family and was able to build a working virology laboratory.[16] He later joined the National Foundation for Infantile Paralysis's polio project established by President Franklin D. Roosevelt.[16][25]

Extensive publicity and fear of polio led to much increased funding, reaching $67 million by 1955. Despite the funding, research continued on live vaccines.[26][17]: 85–87 Salk decided to use what he believed to be the safer "killed" virus, instead of weakened forms of strains of polio viruses like the ones used contemporaneously by Albert Sabin, who was developing an oral vaccine.[28]

After successful tests on laboratory animals, on July 2, 1952, assisted by the staff at the D.T. Watson Home for Crippled Children, which is now the Education Center at the Watson Institute in Sewickley, Pennsylvania[29]), Salk injected 43 children with his killed-virus vaccine. A few weeks later, Salk injected children at the Polk State School for the Retarded and Feeble-minded. He vaccinated his own children in 1953.[30][31] In 1954 he tested the vaccine on about one million children, known as the polio pioneers. The vaccine was announced as safe on April 12, 1955.[26][25][32][33][34]
The project became large, involving 100 million contributors to the March of Dimes, and 7 million volunteers.[26][35]: 54 The foundation allowed itself to go into debt to finance the final research required to develop the Salk vaccine.[36] Salk worked incessantly for two-and-a-half years.[26][37]
Salk's inactivated polio vaccine came into use in 1955.[38][39] It is on the World Health Organization's List of Essential Medicines.[40][41]
Becoming a public figure
[edit]Celebrity versus privacy
[edit]
Salk preferred not to have his career as a scientist affected by too much personal attention, as he had always tried to remain independent and private in his research and life, but this proved to be impossible. "Young man, a great tragedy has befallen you—you've lost your anonymity", the television personality Ed Murrow said to Salk shortly after the onslaught of media attention.[42] When Murrow asked him, "Who owns this patent?", Salk replied, "Well, the people I would say. There is no patent. Could you patent the sun?"[43] The vaccine is calculated to be worth $7 billion had it been patented.[44] However, lawyers from the National Foundation for Infantile Paralysis did look into the possibility of a patent, but ultimately determined that the vaccine was not a patentable invention because of prior art.[4]
Salk served on the board of directors of the John D. and Catherine T. MacArthur Foundation.[45]
Author Jon Cohen noted, "Jonas Salk made scientists and journalists alike go goofy. As one of the only living scientists whose face was known the world over, Salk, in the public's eye, had a superstar aura. Airplane pilots would announce that he was on board, and passengers would burst into applause. Hotels routinely would upgrade him into their penthouse suites. A meal at a restaurant inevitably meant an interruption from an admirer. Scientists and journalists who regularly dealt with Salk would come to see him in more human terms, but many still initially approached him with the same drop-jawed wonder, as though some of the stardust might rub off."[46]
For the most part, Salk was "appalled at the demands on the public figure he has become and resentful of what he considers to be the invasion of his privacy", wrote The New York Times, a few months after his vaccine announcement.[34] The Times article noted, "at 40, the once obscure scientist ... was lifted from his laboratory almost to the level of a folk hero." He received a presidential citation, a score of awards, four honorary degrees, half a dozen foreign decorations, and letters from thousands of fellow citizens. His alma mater, City College of New York, gave him an honorary degree as Doctor of Laws. But "despite such very nice tributes", The New York Times wrote, "Salk is profoundly disturbed by the torrent of fame that has descended upon him. ... He talks continually about getting out of the limelight and back to his laboratory ... because of his genuine distaste for publicity, which he believes is inappropriate for a scientist."[34]
During a 1980 interview, 25 years later, he said, "It's as if I've been a public property ever since, having to respond to external, as well as internal, impulses. ... It's brought me enormous gratification, opened many opportunities, but at the same time placed many burdens on me. It altered my career, my relationships with colleagues; I am a public figure, no longer one of them."[42]
Maintaining his individuality
[edit]"If Salk the scientist sounds austere", wrote The New York Times, "Salk the man is a person of great warmth and tremendous enthusiasm. People who meet him generally like him." A Washington newspaper correspondent commented, "He could sell me the Brooklyn Bridge, and I never bought anything before." Geneticist Walter Nelson-Rees called him "a renaissance scientist: brilliant, sophisticated, driven ... a fantastic creature."[47]: 127
He enjoys talking to people he likes, and "he likes a lot of people", wrote the Times. "He talks quickly, articulately, and often in complete paragraphs." And "He has very little perceptible interest in the things that interest most people—such as making money." That belongs "in the category of mink coats and Cadillacs—unnecessary", he said.[34]
Establishing the Salk Institute
[edit]
In the years after Salk's discovery, many supporters, in particular the National Foundation, "helped him build his dream of a research complex for the investigation of biological phenomena 'from cell to society'."[48] Called the Salk Institute for Biological Studies, it opened in 1963 in the San Diego neighborhood of La Jolla, in a purpose-built facility designed by the architect Louis Kahn. Salk believed that the institution would help new and upcoming scientists along in their careers, as he said himself, "I thought how nice it would be if a place like this existed and I was invited to work there."[49]
In 1966, Salk described his "ambitious plan for the creation of a kind of Socratic academy where the supposedly alienated two cultures of science and humanism will have a favorable atmosphere for cross-fertilization."[50] Author and journalist Howard Taubman explained:
Although he is distinctly future-oriented, Dr. Salk has not lost sight of the institute's immediate aim, which is the development and use of the new biology, called molecular and cellular biology, described as part physics, part chemistry and part biology. The broad-gauged purpose of this science is to understand man's life processes.
There is talk here of the possibility, once the secret of how the cell is triggered to manufacture antibodies is discovered, that a single vaccine may be developed to protect a child against many common infectious diseases. There is speculation about the power to isolate and perhaps eliminate genetic errors that lead to birth defects.
Dr. Salk, a creative man himself, hopes that the institute will do its share in probing the wisdom of nature and thus help enlarge the wisdom of man. For the ultimate purpose of science, humanism and the arts, in his judgment, is the freeing of each individual to cultivate his full creativity, in whichever direction it leads. ... As if to prepare for Socratic encounters such as these, the institute's architect, Louis Kahn, has installed blackboards in place of concrete facings on the walls along the walks.[50]
The New York Times, in a 1980 article celebrating the 25th anniversary of the Salk vaccine, described the current workings at the facility, reporting:
At the institute, a magnificent complex of laboratories and study units set on a bluff overlooking the Pacific, Dr. Salk holds the titles of founding director and resident fellow. His own laboratory group is concerned with the immunologic aspects of cancer and the mechanisms of autoimmune disease, such as multiple sclerosis, in which the immune system attacks the body's own tissues.[42]
In an interview about his future hopes at the institute, he said, "In the end, what may have more significance is my creation of the institute and what will come out of it, because of its example as a place for excellence, a creative environment for creative minds."
Francis Crick, co-discoverer of the structure of the DNA molecule, was a leading professor at the institute until his death in 2004. The institute also served as the basis for Bruno Latour and Steve Woolgar's 1979 book Laboratory Life: The Construction of Scientific Facts.[51]
AIDS vaccine work
[edit]Beginning in the mid-1980s, Salk engaged in research to develop a vaccine for AIDS. He cofounded The Immune Response Corporation (IRC) with Kevin Kimberlin and patented Remune, an immunologic therapy, but was unable to secure liability insurance for the product.[52] The project was discontinued in 2007, twelve years after Salk's death.[citation needed]
Salk's biophilosophy
[edit]
In 1966, The New York Times referred to him as the "Father of Biophilosophy." According to Times journalist and author Howard Taubman, "he never forgets ... there is a vast amount of darkness for man to penetrate. As a biologist, he believes that his science is on the frontier of tremendous new discoveries; and as a philosopher, he is convinced that humanists and artists have joined the scientists to achieve an understanding of man in all his physical, mental and spiritual complexity. Such interchanges might lead, he would hope, to a new and important school of thinkers he would designate as biophilosophers."[50] Salk told his cousin, Joel Kassiday, at a meeting of the Congressional Clearinghouse on the Future on Capitol Hill in 1984 that he was optimistic that ways to prevent most human and animal diseases would eventually be developed. Salk said people must be prepared to take prudent risks, since "a risk-free society would become a dead-end society" without progress.
Salk describes his biophilosophy as the application of a "biological, evolutionary point of view to philosophical, cultural, social and psychological problems." He went into more detail in two of his books, Man Unfolding, and The Survival of the Wisest. In an interview in 1980, he described his thoughts on the subject, including his feeling that a sharp rise and an expected leveling off in the human population would take place and eventually bring a change in human attitudes:
I think of biological knowledge as providing useful analogies for understanding human nature. ... People think of biology in terms of such practical matters as drugs, but its contribution to knowledge about living systems and ourselves will in the future be equally important. ... In the past epoch, man was concerned with death, high mortality; his attitudes were antideath, antidisease", he says. "In the future, his attitudes will be expressed in terms of prolife and prohealth. The past was dominated by death control; in the future, birth control will be more important. These changes we're observing are part of a natural order and to be expected from our capacity to adapt. It's much more important to cooperate and collaborate. We are the co-authors with nature of our destiny.[42]
His definition of a biophilosopher is "Someone who draws upon the scriptures of nature, recognizing that we are the product of the process of evolution, and understands that we have become the process itself, through the emergence and evolution of our consciousness, our awareness, our capacity to imagine and anticipate the future, and to choose from among alternatives."[53]
Just prior to his death, Salk was working on a new book along the theme of biophilosophy, privately reported to be titled Millennium of the Mind.
Personal life and death
[edit]The day after his graduation from medical school in 1939, Salk married Donna Lindsay, a master's candidate at the New York College of Social Work. David Oshinsky writes that Donna's father, Elmer Lindsay, "a wealthy Manhattan dentist, viewed Salk as a social inferior, several cuts below Donna's former suitors." Eventually, her father agreed to the marriage on two conditions: first, Salk must wait until he could be listed as an official M.D. on the wedding invitations, and second, he must improve his "rather pedestrian status" by giving himself a middle name."[17]: 99
They had three children: Peter, who also became a physician and a part-time professor of infectious diseases at the University of Pittsburgh;[30][31][54] Darrell, who also worked with vaccines and genetics and eventually retired from the pediatrics faculty at the University of Washington School of Medicine;[55] and Jonathan Salk, an adult and child psychiatrist and Assistant Clinical Professor at the David Geffen School of Medicine at UCLA.[56] They divorced in 1968, and Salk married French painter Françoise Gilot two years later.
On June 23, 1995, Salk died from heart failure at age 80 in La Jolla.[57] He was buried at El Camino Memorial Park in San Diego.[58][59]
Honors and recognition
[edit]
- 1955, one month after the vaccine announcement, he was honored by the Commonwealth of Pennsylvania, where he was given their "highest award for services" by Governor George M. Leader, Meritorious Service Medal, where the governor added,
... in recognition of his 'historical medical' discovery ... Dr. Salk's achievement is meritorious service of the highest magnitude and dimension for the commonwealth, the country and mankind." The governor, who had three children, said that "as a parent he was 'humbly thankful to Dr. Salk,' and as Governor, 'proud to pay him tribute'.[60]
- 1955, City University of New York creates the Salk Scholarship fund which it awards to multiple outstanding pre-med students each year
- 1956, awarded the Lasker Award
- 1957, the Municipal Hospital building, where Salk conducted his polio research at the University of Pittsburgh, is renamed Jonas Salk Hall and is home to the university's School of Pharmacy and Dentistry.[61]
- 1958, awarded the James D. Bruce Memorial Award
- 1958, elected to the Polio Hall of Fame, which was dedicated in Warm Springs, Georgia
- 1975, awarded the Jawaharlal Nehru Award and the Congressional Gold Medal
- 1976, awarded the Academy of Achievement's Golden Plate Award[62]
- 1976, named the Humanist of the Year by the American Humanist Association
- 1977, awarded the Presidential Medal of Freedom from President Jimmy Carter, with the following statement accompanying the medal:
Because of Doctor Jonas E. Salk, our country is free from the cruel epidemics of poliomyelitis that once struck almost yearly. Because of his tireless work, untold hundreds of thousands who might have been crippled are sound in body today. These are Doctor Salk's true honors, and there is no way to add to them. This Medal of Freedom can only express our gratitude, and our deepest thanks.
- 1981, decorated by the Italian government on January 3 as a Grand Officer of the Order of Merit of the Italian Republic[63]
- 1996, the March of Dimes Foundation created an annual $250,000 cash "Prize" to outstanding biologists as a tribute to Salk.[64]
- 2006, the United States Postal Service issued a 63-cent Distinguished Americans series postage stamp in his honor.
- 2007, California Governor Arnold Schwarzenegger and First Lady Maria Shriver inducted Salk into the California Hall of Fame.[65]
- 2009, BBYO boys chapter chartered in his honor in Scottsdale, Arizona, Named "Jonas Salk AZA #2357"
- Schools in Mesa, Arizona; The Jonas E Salk Middle School of Spokane Schools District No. 81 in Spokane, Washington; Tulsa, Oklahoma; Bolingbrook, Illinois; Levittown, New York; Old Bridge, New Jersey; Merrillville, Indiana; Sacramento, California; and Mira Mesa, California; are named after him.
- 2012, October 24, in honor of his birthday, has been named "World Polio Day", and was originated by Rotary International over a decade earlier.[66]
- 2014, On the 100th anniversary of Salk's birth, a Google Doodle was created to honor the physician and medical researcher. The doodle shows happy and healthy children and adults playing and going about their lives with two children hold up a sign saying, "Thank you, Dr. Salk!"[3][67]
Documentary films
[edit]- In early 2009, the American Public Broadcasting Service aired its new documentary film, American Experience: The Polio Crusade.[23]
- On April 12, 2010, to help celebrate the 55th anniversary of the Salk vaccine, a new 66-minute documentary, The Shot Felt 'Round the World, had its world premiere. Directed by Tjardus Greidanus[68] and produced by Laura Davis,[69] the documentary was conceived by Hollywood screenwriter and producer Carl Kurlander to bring "a fresh perspective on the era."[70]
- In 2014, actor and director Robert Redford, who was once struck with a mild case of polio when he was a child, directed a documentary about the Salk Institute in La Jolla.[71]
- In Chapter 10 of the 2018 season of Genius Michael McElhatton portrays Salk in a short cameo where he is on a date with Françoise Gilot.[72]
Selected publications
[edit]See also
[edit]References
[edit]- ^ a b c d e f g h i j k "Dr. Jonas Salk, Whose Vaccine Turned Tide on Polio, Dies at 80". The New York Times. June 24, 1995. Archived from the original on October 13, 2022. Retrieved October 23, 2020.
- ^ a b "About Jonas Salk – Salk Institute for Biological Studies". Salk Institute for Biological Studies. Archived from the original on November 21, 2015. Retrieved February 22, 2016.
- ^ a b Hiltzik, Michael (October 28, 2014). "On Jonas Salk's 100th birthday, a celebration of his polio vaccine". Los Angeles Times. Archived from the original on October 28, 2014. Retrieved October 28, 2014.
- ^ a b "The Real Reason Why Salk Refused to Patent the Polio Vaccine". Biotech-now.org. Archived from the original on March 24, 2020. Retrieved July 14, 2014.
- ^ Tan, Siang Yong; Ponstein, Nate (January 2019). "Jonas Salk (1914–1995): A vaccine against polio". Singapore Medical Journal. 60 (1): 9–10. doi:10.11622/smedj.2019002. ISSN 0037-5675. PMC 6351694. PMID 30840995.
- ^ Estivariz, Concepcion F.; Link-Gelles, Ruth; Shimabukuro, Tom (2021). "Chapter 18: Poliomyelitis". In Hall, Elisha; Wodi, A. Patricia; Hamborsky, Jennifer; Morelli, Valerie; Schillie, Sarah (eds.). Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book) (14th ed.). Centers for Disease Control and Prevention (CDC, US). Archived from the original on May 10, 2025..
- ^ Jacobs, Charlotte DeCroes. "Vaccinations have always been controversial in America: Column" Archived September 29, 2022, at the Wayback Machine, USA Today, August 4, 2015
- ^ "UC San Diego Library Receives Personal Papers of Jonas Salk" Archived September 29, 2022, at the Wayback Machine, Newswise, March 20, 2014
- ^ San Diego Union Tribune, 20 March 2014: "UCSD to house Salk's papers" Archived May 6, 2016, at the Wayback Machine, accessed July 3, 2015.
- ^ "Selected Questions from Student Interviews: Darrell Salk, M.D." The Jonas Salk Center. 2001. Archived from the original on January 30, 2010. Retrieved April 15, 2020.
- ^ Charlotte DeCroes Jacobs (2015). Jonas Salk: A Life. Oxford University Press. pp. 45–. ISBN 978-0-19-933443-8. Archived from the original on July 1, 2023. Retrieved April 2, 2020.
- ^ "Jonas Edward Salk facts, information, pictures - Encyclopedia.com articles about Jonas Edward Salk". www.encyclopedia.com. Archived from the original on July 25, 2016. Retrieved April 25, 2015.
- ^ Dr. Lee Salk, Child Psychologist And Popular Author, Dies at 65 – New York Times Archived July 5, 2020, at the Wayback Machine. Retrieved August 15, 2011.
- ^ Roberts, Sam (July 27, 2012). "New York Census Data, Centuries Old, Is Now Online". Archived from the original on July 27, 2012. Retrieved March 26, 2018.
- ^ City College of New York Microcosm Yearbook, 1934
- ^ a b c d e f Bookchin, Debbie, and Schumacher, Jim. The Virus and the Vaccine, Macmillan (2004) ISBN 0-312-34272-1
- ^ a b c d e f g h Oshinsky, David M. (2005). Polio: An American Story. Oxford: Oxford University Press. ISBN 978-0-19-515294-4. OCLC 1031748949.
- ^ a b Sherrow, Victoria: Jonas Salk, Revised Edition (2009), p. 12
- ^ "Jonas Salk Biography and Interview". www.achievement.org. American Academy of Achievement. Archived from the original on March 29, 2023. Retrieved April 7, 2020.
- ^ "Jonas Salk Biography and Interview". www.achievement.org. American Academy of Achievement. Archived from the original on March 29, 2023. Retrieved April 3, 2019.
- ^ "Jonas Salk Interview – page 2 / 8 – Academy of Achievement". Archived from the original on July 22, 2015. Retrieved August 14, 2015.
- ^ Bankston, John (2002). Jonas Salk and the Polio Vaccine. Bear, Delaware: Mitchell Lane Publishers. pp. 30–32.
- ^ a b "American Experience: The Polio Crusade" Los Angeles Times, Television Review, February 2, 2009
- ^ McPherson, Stephanie (2002). Jonas Salk: Conquering Polio. Minneapolis, Minnesota: Lerner Publications Company. pp. 33–37. ISBN 9780822549642.
- ^ a b Wisdom magazine, August 1956 pp. 6–15
- ^ a b c d e O'Neill, William L. (1989). American High: The Years of Confidence, 1945–1960. New York: Simon and Schuster. ISBN 0-02-923679-7.
- ^ Rose DR (2004). "Fact Sheet—Polio Vaccine Field Trial of 1954." March of Dimes Archives. 2004 02 11.
- ^ "Jonas Salk and Albert Bruce Sabin". Science History Institute. January 8, 2017. Archived from the original on February 23, 2018. Retrieved June 15, 2020.
- ^ "The Watson Institute special education history". The Watson Institute. Archived from the original on November 11, 2021. Retrieved November 11, 2021.
- ^ a b "Among The 1st To Get A Polio Vaccine, Peter Salk Says Don't Rush A COVID-19 Shot". NPR. May 30, 2020. Archived from the original on December 27, 2020. Retrieved December 26, 2020.
- ^ a b "From Polio To The COVID Vaccine, Dr. Peter Salk Sees Great Progress". NPR. December 26, 2020. Archived from the original on December 27, 2020. Retrieved December 26, 2020.
- ^ "Complete Program Transcript. The Polio Crusade. WGBH American Experience". PBS. Archived from the original on October 28, 2014. Retrieved July 14, 2014.
- ^ "Anti-polio Vaccine Guaranteed by Salk," Archived May 1, 2022, at the Wayback Machine The New York Times, November 13, 1953
- ^ a b c d "What Price Fame—to Dr. Salk". The New York Times. July 17, 1955. Archived from the original on May 2, 2021. Retrieved July 22, 2018.
- ^ Offit, Paul (2005). "The Cutter incident, 50 years later" (PDF). N. Engl. J. Med. 352 (14): 1411–1412. doi:10.1056/NEJMp048180. PMID 15814877. Archived from the original (PDF) on July 26, 2008. Retrieved April 16, 2010.
- ^ Fleischer, Doris Z. The Disability Rights Movement: From Charity to Confrontation Temple University Press (2001)
- ^ Denenberg, Dennis, and Roscoe, Lorraine. 50 American Heroes Every Kid Should Meet Millbrook Press (2006)
- ^ "Polio vaccines: WHO position paper, March, 2016" (PDF). Wkly Epidemiol Rec. 91 (12): 145–168. March 25, 2016. PMID 27039410. Archived (PDF) from the original on June 3, 2016.
- ^ Bazin, H. (2011). Vaccination: A History. John Libbey Eurotext. p. 395. ISBN 9782742007752. Archived from the original on September 8, 2017.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ a b c d Glueck, Grace. "Salk Studies Man's Future" Archived March 11, 2014, at the Wayback Machine The New York Times, April 8, 1980
- ^ Smith, Jane S. (1990). Patenting the Sun: Polio and The Salk Vaccine. New York: William Morrow. ISBN 0-688-09494-5.
- ^ "How Much Money Did Jonas Salk Potentially Forfeit By Not Patenting The Polio Vaccine?". Forbes. August 8, 2012. Archived from the original on October 6, 2014. Retrieved September 30, 2014.
- ^ Sherrow, Victoria (2009). Jonas Salk, Revised Edition. Infobase Publishing. p. 99. ISBN 9781438104119.
- ^ Cohen, Jon (2001). Shots in the Dark: The Wayward Search for an AIDS Vaccine. New York: W.W. Norton & Co. p. 88. ISBN 0-393-05027-0.
- ^ Gold, Michael. A Conspiracy of Cells, State Univ. of NY Press, (1985)
- ^ "Salk 25 years after vaccine Archived March 14, 2023, at the Wayback Machine", Detroit Free Press, April 9, 1980, p. 31.
- ^ Johnson, George (November 25, 1990). "Once Again, A MAN WITH A MISSION". The New York Times. Archived from the original on October 29, 2021. Retrieved October 13, 2021.
- ^ a b c Taubman, Howard. "Father of Biophilosophy" Archived March 11, 2014, at the Wayback Machine The New York Times, November 11, 1966
- ^ Latour, Bruno; Woolgar, Steve (September 21, 1986). Laboratory Life. Princeton University Press. ISBN 9780691028323. Archived from the original on April 1, 2017. Retrieved May 4, 2017.
- ^ Remune (HIV-1 Immunogen, Salk vaccine) Archived March 21, 2009, at the Wayback Machine AIDSmeds.com
- ^ "Man Evolving" video interview, 1985, 28 minutes
- ^ Salk, Peter L. (January 21, 2021). "Polio vaccines brought an earlier epidemic under control. New vaccines can end this current plague". The Globe and Mail. Archived from the original on February 5, 2023. Retrieved February 5, 2023.
My father ... found himself at the forefront of research toward the development of a polio vaccine
- ^ "Darrell Salk relates a tale of two viruses" (Press release). University District, Seattle: University of Washington School of Medicine. February 9, 2021. Archived from the original on July 4, 2022. Retrieved August 17, 2022.
- ^ "Bios". A New Reality. Archived from the original on August 10, 2023. Retrieved August 10, 2023.
- ^ The New York Times, Dr. Jonas Salk, Whose Vaccine Turned Tide on Polio, Dies at 80 Archived October 13, 2022, at the Wayback Machine June 25, 1995. Retrieved July 15, 2010.
- ^ Stone, Ken (December 3, 2012). "David Copley Burial Is Set for Monday at El Camino Memorial Park in San Diego". La Jolla, CA Patch. Retrieved January 16, 2025.
- ^ Page •, Eric S. (October 27, 2022). "Corpse Pride: We Know Where the Bodies Are Buried This Halloween, San Diego". NBC 7 San Diego. Retrieved January 16, 2025.
- ^ Weart, William G. "Salk is Honored by Pennsylvania" Archived May 1, 2021, at the Wayback Machine The New York Times, May 11, 1955, accessed September 14, 2015
- ^ Alberts, Robert C. (1986). Pitt: The Story of the University of Pittsburgh, 1787–1987. Pittsburgh, Pennsylvania: University of Pittsburgh Press. p. 263. ISBN 0-8229-1150-7. Archived from the original on May 20, 2011. Retrieved December 7, 2009.
- ^ "Golden Plate Awardees of the American Academy of Achievement". www.achievement.org. American Academy of Achievement. Archived from the original on December 12, 2017. Retrieved April 7, 2020.
- ^ "Salk, Prof. Jonas". quirinale.it (in Italian). Archived from the original on April 15, 2021. Retrieved December 30, 2020.
- ^ "March of Dimes Awards $250,000 Prize to Scientists Unraveling the Causes of Muscular Dystrophy". Lifesciencesworld.com. Archived from the original on March 11, 2014. Retrieved July 14, 2014.
- ^ Salk inducted into California Hall of Fame Archived January 10, 2008, at the Wayback Machine, California Museum.
- ^ CDC announces World Polio Day Archived January 23, 2023, at the Wayback Machine, CDC, October 19, 2012
- ^ The Guardian: Jonas Salk Google doodle Archived March 9, 2023, at the Wayback Machine, accessdate: September 14, 2015
- ^ "IMDb bio of director Tjardus Greidanus". IMDb. Archived from the original on January 18, 2015. Retrieved October 28, 2014.
- ^ "IMDb bio of Laura Davis". IMDb. Archived from the original on January 15, 2015. Retrieved October 28, 2014.
- ^ "Film reveals Pittsburgh's polio stories" Archived June 23, 2011, at the Wayback Machine Pittsburgh Post-Gazette, April 14, 2010
- ^ Bell, Diane (June 30, 2014). "Director Robert Redford gives sneak preview in La Jolla of his Salk Institute documentary film". The San Diego Union-Tribune. Archived from the original on August 2, 2020. Retrieved April 29, 2020.
- ^ "Picasso: Chapter 10". IMDb. Archived from the original on April 28, 2022. Retrieved January 5, 2021.
Further reading
[edit]- Bourgeois, Suzanne. Genesis of the Salk Institute: The Epic of Its Founders (University of California Press, 2013)
- Jacobs, Charlotte DeCroes. Jonas Salk: A Life, Oxford Univ. Press (2015), scholarly biography
- Kluger, Jeffrey. Splendid Solution: Jonas Salk and the Conquest of Polio, (Berkley Books, 2006), history of the polio vaccine
- Oshinsky, David M. Polio: an American story (Oxford University Press, 2005) excerpt.
- Sahu, Hemlata, et al. "Jonas Salk (1914-1995): Pioneering the Fight Against Polio and Beyond." Cureus 16.9 (2024): e69681. online
- Weintraub, B. "Jonas Salk (1914–1995) and the first vaccine against polio". Israel Chemist and Engineer. July 2020, iss. 6. pp. 31–34
External links
[edit]- The American Experience: The Polio Crusade video, 1 hr. by PBS
- "Legacy of Salk Institute", video, 30 minutes, history of Salk vaccine
- "Polio Vaccine" intro., Britannica, video, 1 minute
- Jonas Salk Legacy Foundation
- Jonas Salk Trust
- Salk Institute for Biological Studies
- Documents regarding Jonas Salk and the Salk Polio Vaccine, Dwight D. Eisenhower Presidential Library
- 1985 Open Mind interview with Richard D. Heffner: Man Evolving...
- Pittsburgh Post-Gazette feature on Jonas Salk and the Polio cure 50 years later Archived September 5, 2008, at the Wayback Machine
- The Salk School of Science (New York, New York)
- US 5256767: Vaccine against HIV
- The short film Man Evolving (1985) is available for free viewing and download at the Internet Archive.
- Register of Jonas Salk Papers, 1926–1991 – MSS 1, held in the UC San Diego Library's Special Collections & Archives
Jonas Salk
View on GrokipediaEarly Life and Education
Childhood and Family Background
Jonas Edward Salk was born on October 28, 1914, in New York City to Russian-Jewish immigrant parents Daniel B. Salk and Dora Press Salk.[1] He was the eldest of three sons, followed by brothers Herman, who later became a veterinarian, and Lee, a child psychologist.[7][8] The Salk family originated from Ashkenazi Jewish backgrounds, with Dora having emigrated from Minsk at age twelve, reflecting the waves of Eastern European Jewish immigration to the United States in the early 20th century.[9] Daniel worked in the garment industry, supporting a modest household that initially resided in East Harlem before relocating to the Bronx.[9] Despite their own lack of formal education, the parents instilled a profound value on learning and self-improvement in their children, viewing education as a pathway to upward mobility amid economic hardship.[7][10] Salk's early childhood was marked by a serious demeanor, with few recounted fond memories, though he displayed an innate curiosity toward the human condition rather than purely scientific pursuits.[7] Raised in an environment that emphasized discipline, thrift, and intellectual rigor, he became the first in his family to pursue higher education, a distinction encouraged by his parents' aspirations for their sons to transcend immigrant limitations.[7][11] This family ethos, rooted in Jewish cultural traditions of scholarship and resilience, profoundly shaped his formative years and later commitment to public good.[10]Academic Training and Influences
Salk graduated from Townsend Harris High School, a public preparatory institution for intellectually gifted students in New York City, at age 15 in 1931.[12][13] He enrolled at the City College of New York, the first in his immigrant family to attend college, and earned a Bachelor of Science degree in chemistry in 1934.[11][7] Initially drawn to law, Salk pivoted toward medical science amid his undergraduate coursework, influenced by his parents' strong emphasis on education as a path to advancement.[7] Salk then attended New York University School of Medicine, obtaining his Doctor of Medicine degree in 1939.[1][11] A formative moment came during a second-year lecture contrasting immunization approaches—killed vaccines for diphtheria and tetanus versus live ones for others—which Salk later recalled as revealing an unresolved contradiction that ignited his focus on vaccine mechanisms: "What struck me was that both statements couldn’t be true."[7] In his final medical school year, Salk investigated influenza viruses, devising a technique to immunize using inactivated strains, an early indicator of his virological interests.[7] He also developed a professional tie with Thomas Francis Jr., a virologist whose expertise in vaccine trials and epidemiology would shape Salk's subsequent research methods, beginning with collaborative work shortly after graduation.[1][11]Initial Scientific Career
Postgraduate Work and Military Service
Following receipt of his medical degree from New York University School of Medicine in 1939, Salk undertook a two-year internship at Mount Sinai Hospital in New York City, commencing in March 1940 and concluding in 1942.[14][15] During this period, he divided his efforts between clinical duties and laboratory research, including work on viral pathogens under the guidance of physician Thomas McPherson Brown, which deepened his interest in virology and immunology.[16] In 1942, shortly after the United States entered World War II, Salk joined the University of Michigan School of Public Health on a National Research Council fellowship to assist virologist Thomas Francis Jr. in developing an influenza vaccine for military use.[1][17] Their efforts, supported by U.S. Army funding, focused on inactivated-virus techniques to immunize troops against influenza A and B strains, amid concerns over outbreaks in crowded training camps and combat zones.[18] By 1943, Salk and Francis had produced a killed-virus vaccine that proved effective in trials, enabling widespread administration to over 4 million U.S. servicemen by war's end; Salk contributed to strain isolation and purification processes, identifying antigenic variants of influenza A.[19][20] Salk's wartime research avoided direct enlistment, as he opted for civilian scientific contributions over a commissioned medical role in the Army, a decision facilitated by the fellowship's alignment with national defense priorities.[21] This period advanced his expertise in vaccine production and epidemiology, laying groundwork for subsequent virological pursuits, and culminated in his promotion to assistant professor of epidemiology at Michigan by 1946.[1][22]Early Vaccine Research
In 1942, Jonas Salk joined the University of Michigan as a research fellow under virologist Thomas Francis Jr. to work on influenza vaccine development, motivated by the need to protect military personnel amid World War II outbreaks.[1][23] Their efforts focused on creating an inactivated vaccine using virus strains grown in embryonated chicken eggs and treated with formalin to kill the virus while preserving immunogenicity.[24] This approach built on earlier virology advances, emphasizing safety through inactivation to prevent disease while inducing immunity.[25] By 1945, Salk and Francis had produced the first approved inactivated influenza vaccine, which was deployed by the U.S. Army to immunize troops against seasonal and pandemic strains, demonstrating efficacy in reducing infection rates among vaccinated personnel.[26][1] Salk's contributions included refining purification techniques and conducting serological studies to confirm antibody responses, advancing him to assistant professor by 1946.[1] The vaccine's success validated the killed-virus strategy, which Salk later adapted for poliovirus, though it required annual updates due to influenza's antigenic drift.[23] This period honed Salk's expertise in vaccine production and testing protocols, including large-scale trials that prioritized empirical safety data over live-virus risks, influencing his subsequent virology research.[19][27]Polio Vaccine Development
Research Methodology and Breakthroughs
Jonas Salk's research methodology for the polio vaccine centered on developing an inactivated poliovirus vaccine (IPV) using killed virus particles to induce immunity without the risk of causing infection, diverging from the era's preference for live attenuated strains.[1] Building on John Enders, Thomas Weller, and Frederick Robbins' 1949 breakthrough in culturing poliovirus in non-neural monkey kidney cells, Salk propagated large quantities of the three poliovirus serotypes (Types I, II, and III) in these cultures at the University of Pittsburgh starting in 1947.[28] [10] This enabled scalable production, overcoming prior limitations of neural tissue propagation that risked contamination and ethical issues.[28] The inactivation process involved treating the harvested virus with formalin (a 1:250 concentration of formaldehyde solution) to destroy viral infectivity while preserving antigenic properties essential for antibody production, a technique refined by Salk's team including virologist Julius Youngner.[28] Safety and potency were verified through rigorous laboratory assays measuring residual live virus and immunogenicity in animal models before human application. Initial testing occurred in 1953, with Salk administering the vaccine to himself, his family, laboratory staff, and over 15,000 volunteers in pilot studies, demonstrating a 4- to 16-fold rise in antibody titers without adverse effects.[2] [28] These empirical results countered skepticism from peers who doubted killed viruses could elicit durable immunity, as evidenced by serological data showing type-specific protection.[10] The breakthrough culminated in the 1954 Francis Field Trial, a double-blind, placebo-controlled study involving 1.8 million children, which confirmed the vaccine's 72% efficacy against paralytic polio.[28] On April 12, 1955, the vaccine was declared safe and effective at the University of Michigan's Rackham Amphitheatre, leading to licensure and rapid deployment that reduced U.S. polio cases from approximately 29,000 in 1955 to under 6,000 by 1957.[10] This success validated Salk's first-principles approach prioritizing causal inactivation of the pathogen over attenuation, grounded in verifiable antibody responses and epidemiological outcomes rather than theoretical risks of reversion in live vaccines.[4]Clinical Trials, Testing Ethics, and Approval
The 1954 field trials of Jonas Salk's inactivated polio vaccine (IPV), formally known as the Francis Field Trial, represented the largest clinical trial in medical history up to that point, involving approximately 1.8 million children across the United States, primarily first- and second-graders in 44 states.[29][3] Organized by the National Foundation for Infantile Paralysis (NFIP) and directed by epidemiologist Thomas Francis Jr. at the University of Michigan, the trials commenced on April 26, 1954, at sites such as Franklin Sherman Elementary School in McLean, Virginia.[29] The study employed a hybrid design: in 33 states, it used an observed control approach comparing vaccinated children (about 650,000 received two or three doses of vaccine) to unvaccinated peers, while in 11 states, a double-blind placebo-controlled method was implemented, with roughly 750,000 children receiving placebo injections and the remainder serving as uninoculated controls.[3][30] This structure aimed to assess efficacy against paralytic poliomyelitis while minimizing bias, with participants monitored for polio cases through surveillance systems reporting to Francis's evaluation committee.[31] Results were analyzed over the subsequent polio season, culminating in an announcement by Francis on April 12, 1955, at the University of Michigan's Rackham Amphitheater, where he declared the vaccine 80-90% effective in preventing paralytic polio based on statistical evidence from the trial data.[3][31] In the placebo-controlled areas, paralytic polio incidence was 71% lower in vaccinated groups compared to placebo recipients, while observed control areas showed even higher relative protection rates, with fewer than expected cases among the vaccinated.[30] These findings, derived from rigorous statistical methods including randomization where applied and adjustment for confounding factors like age and location, provided strong evidence of the vaccine's protective effect without evidence of increased risk from the killed-virus formulation.[31] Ethical considerations in the trials reflected mid-20th-century standards, prioritizing communal benefit amid a polio epidemic that paralyzed thousands annually, though retrospective critiques highlight limitations in modern informed consent protocols. Parental permission was secured for participation, typically through school-based opt-in processes, with the NFIP emphasizing voluntary involvement and providing basic information on potential risks and benefits.[32] Earlier phases of Salk's research, from 1952 onward, involved testing on over 7,000 children in institutions such as mental hospitals and orphanages, where consent was often obtained from guardians but lacked the detailed disclosure required today, raising questions about autonomy for vulnerable populations.[33] The use of placebos in healthy children was justified by the absence of an approved alternative and the trial's observational safeguards, though some contemporaries debated the ethics of withholding a promising intervention from controls during an outbreak-prone season; no formal ethical oversight body like today's IRBs existed, and the trials proceeded under NFIP funding with public support driven by fear of polio.[34] Salk himself inoculated his own children and family in 1953 as a demonstration of confidence, aligning with era practices where researchers often self-tested.[2] Following the announcement, the U.S. Public Health Service licensed Salk's IPV for commercial production on the same day, April 12, 1955, enabling immediate nationwide distribution by manufacturers like Eli Lilly and Wyeth.[2][35] This expedited approval, based on the trial's efficacy data and prior safety assessments in smaller cohorts, marked a pivotal regulatory milestone, though it preceded the Cutter Incident later that year, which exposed manufacturing inconsistencies rather than flaws in the trial design or vaccine formulation itself.[2] The licensing spurred mass immunization campaigns, reducing U.S. polio cases dramatically by 1957.[2]Post-Approval Challenges and Cutter Incident
Following the announcement of the Salk polio vaccine's efficacy on April 12, 1955, U.S. health authorities licensed it for public use the same day, prompting a rapid mass immunization campaign targeting schoolchildren.[36] Five manufacturers, including Cutter Laboratories, received production licenses and distributed millions of doses within weeks to meet overwhelming demand, with initial shipments exceeding 4 million doses by late April.[36] This accelerated rollout, driven by public urgency to curb polio epidemics, exposed vulnerabilities in scaling up production from laboratory conditions to industrial levels, as manufacturers adapted Salk's inactivation protocol—using formaldehyde to kill poliovirus grown in monkey kidney cells—without uniform mastery of the process.[37] By mid-April 1955, reports surfaced of polio paralysis in vaccinated children in California, Idaho, and other states, with the first clusters appearing just 13 days after initial distributions.[36] Investigations pinpointed defective batches from Cutter Laboratories, where approximately 120,000 doses contained live poliovirus due to incomplete inactivation during manufacturing; the failure stemmed from inadequate testing of seed virus pools and final products, including insufficient tissue culture assays to detect residual live virus, compounded by reliance on less sensitive animal safety tests.[37] Among roughly 200,000-250,000 children who received Cutter's vaccine, over 250 developed polio, including more than 200 paralytic cases and at least 10 deaths directly attributable to the live virus in the vaccine; secondary transmission affected family members and contacts, adding over 100 additional cases.[38][36] Jonas Salk, who had emphasized rigorous safety in his trials, publicly defended the vaccine's core method, attributing the outbreak solely to Cutter's production lapses rather than flaws in the formulation itself, as batches from other manufacturers proved safe.[36] The incident triggered an immediate nationwide suspension of polio vaccinations on April 27, 1955, eroding short-term public confidence and prompting congressional hearings that revealed regulatory shortcomings, including hasty licensing by the National Institutes of Health's Division of Biologic Standards amid political pressure.[38][36] Key officials, such as the Laboratory of Biologics Control director, resigned amid blame for lax oversight, while Cutter faced lawsuits establishing strict liability for vaccine makers without proving negligence.[36] In response, authorities implemented enhanced manufacturing standards, mandating multiple tissue culture tests for virus inactivation, stricter potency assays, and federal inspections before release; vaccinations resumed in the fall of 1955 under these protocols, with the program's overall efficacy soon demonstrated by a 90% drop in U.S. polio cases by 1957.[37][38] The Cutter episode underscored the causal risks of prioritizing speed over validation in vaccine scaling, yet reinforced the inactivated vaccine's safety when produced correctly, paving the way for sustained eradication efforts without implicating Salk's research integrity.[37]Intellectual Property and Patent Decision
Rationale for Non-Patenting
Jonas Salk decided against pursuing a patent for his inactivated polio vaccine, announced as safe and effective on April 12, 1955. During a CBS See It Now interview with Edward R. Murrow on the same day, when asked who owned the patent, Salk replied, "Well, the people, I would say. There is no patent. Could you patent the sun?"[39][40] This reflected his view that the vaccine, developed to combat a public health crisis, inherently belonged to humanity rather than any individual or entity seeking exclusive rights.[10] The decision aligned with the practical realities of the vaccine's development, primarily funded by the National Foundation for Infantile Paralysis (later known as the March of Dimes), which raised funds through widespread public donations—reaching an annual budget of $50 million by 1955 from contributions by over 80 million Americans.[39] Foundation lawyers had evaluated patent options but concluded that key techniques, such as viral inactivation with formaldehyde, built on prior scientific knowledge and lacked sufficient novelty to secure a defensible patent, potentially inviting costly litigation.[39] With research costs already covered by nonprofit public funding rather than private investment, patenting offered no economic necessity for recouping expenses and could have delayed widespread production by restricting licensing to pharmaceutical manufacturers.[39][40] Salk's stance emphasized a humanitarian priority, prioritizing eradication of polio over personal or institutional profit, consistent with his broader philosophy of science serving the public good.[10] This approach facilitated rapid global distribution, as the foundation freely licensed the vaccine to multiple companies, enabling mass immunization campaigns that reduced U.S. polio cases from approximately 29,000 in 1955 to under 6,000 by 1957.[10] While often framed as altruism, the non-patenting reflected an interplay of ethical conviction, legal pragmatism, and the nonprofit funding model that obviated the need for monopoly protections typical in privately financed innovations.[39]Economic Incentives, Criticisms, and Long-Term Implications
Salk's decision to forgo patenting the inactivated polio vaccine (IPV) relinquished potential royalties estimated at $7 billion over the patent's projected lifespan, calculated from global vaccination volumes, average dosing costs adjusted for inflation, and a 25-33% markup for patent-related expenses from 1960 to 2010.[41] This figure assumes a viable 20-year patent from 1955, during which the vaccine's widespread adoption—driven by public demand and nonprofit distribution—generated substantial market value without exclusive licensing. However, the choice aligned with economic realities shaped by the National Foundation for Infantile Paralysis (NFIP), which invested over $50 million in research and trials funded by public donations, rendering a strong patent claim improbable due to extensive prior art and the foundation's de facto ownership interests.[39] Non-patenting permitted multiple pharmaceutical firms to manufacture the vaccine under NFIP oversight, avoiding monopoly pricing that could have raised costs by 25% or more and delayed accessibility, though it shifted financial incentives toward government and nonprofit procurement rather than private royalties.[41][39] Critics within the pharmaceutical sector, including executives from firms like Eli Lilly involved in early production, contended that forgoing patents undermined long-term incentives for private investment in vaccine research, where high development risks and low profit margins already deterred commercial engagement compared to therapeutic drugs.[39] This perspective holds that Salk's model, reliant on nonprofit funding, succeeded in a unique public mobilization era but failed to account for the need for intellectual property protections to recoup costs in market-driven systems, potentially contributing to vaccines' historical underfunding relative to other pharmaceuticals.[42] Salk's public rhetoric, such as likening the vaccine to the "sun" during a 1955 interview, has been characterized as economically oversimplified, obscuring the pragmatic legal barriers—lack of novelty per NFIP and university attorneys—and fostering a narrative that undervalues patents' role in fostering innovation amid uncertain returns.[43][39] The non-patenting facilitated rapid mass production and distribution, correlating with a precipitous decline in U.S. polio cases from approximately 45,000 annually pre-1955 to 910 by 1962, accelerating domestic control and informing global campaigns that certified the Americas polio-free by 1994.[4][10] Long-term, it exemplified tensions in biomedical intellectual property, influencing arguments for open-access models in public health crises—such as COVID-19 patent waiver proposals—to prioritize equity over exclusivity, though without resolving manufacturing complexities in low-resource settings.[44] Salk's later pursuit of patents for an HIV vaccine formulation underscored evolving recognition of financial incentives for sustained research, while the polio precedent highlighted how nonprofit-driven openness can expedite eradication efforts but may not scale to profit-dependent industries, where vaccines comprise a smaller R&D share due to thinner margins.[39][2]Public Prominence and Institutional Building
Media Fame and Personal Conflicts
Following the successful announcement of his polio vaccine's efficacy on April 12, 1955, Salk experienced rapid ascent to national celebrity status, with widespread media coverage portraying him as a scientific savior amid the era's polio terror.[45] That same day, he appeared on CBS's See It Now in an interview with Edward R. Murrow, where he detailed the vaccine's inactivated poliovirus mechanism and famously responded to questions about patent ownership by stating, "Well, the people, I would say. There is no patent. Could you patent the sun?"[46] This exchange amplified his public image as a selfless innovator, leading to features in major outlets and accolades like a Congressional Gold Medal later in 1955.[47] The ensuing fame imposed significant personal burdens, as Salk could no longer navigate public spaces without crowds accosting him for autographs or congratulations, effectively curtailing his privacy and mobility.[47] Media saturation positioned him as a folk hero to the public, who credited him personally for vanquishing polio, yet this adulation fostered resentment among virology peers who viewed his prominence as unseemly self-promotion rather than rigorous science.[48] Critics within the field, including figures like Albert Sabin, publicly challenged Salk's approach, with Sabin arguing in media and scientific forums that the killed-virus vaccine risked inadequate long-term immunity and insufficient chemical inactivation testing before mass trials.[49][50] This professional rivalry intensified through public channels, as Sabin's advocacy for his competing live-virus vaccine gained traction post-1955, particularly after the Cutter Incident exposed manufacturing flaws in some Salk vaccine batches, leading to over 200 polio cases and shifting favor toward Sabin's oral version by the early 1960s.[51] Salk's defenders noted Sabin's aggressive media tactics and institutional ties, including Soviet trials that bolstered his claims, but the discourse highlighted Salk's outsider status in elite circles, where his Pittsburgh base and applied focus were dismissed as provincial.[52] Despite public acclaim, these tensions contributed to Salk's marginalization in Nobel considerations and peer networks, with detractors faulting him for monopolizing credit amid collaborative efforts.[48]Establishment of the Salk Institute
In 1957, shortly after the successful deployment of his inactivated poliovirus vaccine, Jonas Salk began planning an independent research institute to promote interdisciplinary collaboration among biologists, physicists, and other scientists aimed at understanding life processes.[6] He envisioned a facility that would transcend traditional academic structures, fostering environments for bold inquiry into biological and evolutionary questions.[1] The Salk Institute for Biological Studies was formally established in 1963 in La Jolla, California, on a coastal site in the Torrey Pines area of San Diego, selected for its inspiring natural setting conducive to creative thought.[6] Funding came primarily from the National Foundation for Infantile Paralysis (later March of Dimes), which provided an initial $20 million grant, supplemented by private donations and government support, enabling construction of laboratories, offices, and residential quarters for resident fellows.[1] Groundbreaking ceremonies occurred on June 2, 1962, for the $14 million project designed by architect Louis I. Kahn, whose modernist concrete structures emphasized symmetry, light, and integration with the landscape.[53] The institute opened its doors to researchers in 1963, though full construction completed in 1965, allowing Salk to relocate from the University of Pittsburgh and assemble an initial cadre of distinguished scientists.[6] Salk served as founding director, prioritizing non-hierarchical governance and long-term, curiosity-driven projects over immediate applied outcomes, with early focuses including molecular biology and neuroscience.[6] This establishment marked Salk's shift from vaccine development to broader biophilosophical pursuits, securing the institute's role as a hub for foundational biological research independent of commercial pressures.[1]Advanced Research Endeavors
AIDS Vaccine Initiatives
In the mid-1980s, Jonas Salk shifted focus from his polio vaccine legacy to developing a therapeutic vaccine against AIDS, aiming to delay disease progression in HIV-infected individuals rather than prevent initial infection.[17][18] Drawing on his experience with inactivated poliovirus, Salk pursued a killed whole-HIV approach, chemically inactivating the virus and depleting it of the gp120 envelope glycoprotein to prioritize T-cell mediated immunity over antibody responses that might exacerbate infection.00407-5/fulltext)[54] This strategy sought to bolster cellular immune responses against HIV's core proteins, addressing the virus's integration into host DNA and its evasion of humoral immunity, challenges absent in polio.[17] In 1987, Salk co-founded the Immune Response Corporation (IRC) with investor Kevin Kimberlin to advance this immunogen, patented as Remune, which used HIV-1 grown in vitro, killed with beta-propiolactone, and stripped of gp120 via detergent treatment.[18] Initial Phase I and II trials, involving HIV-positive participants, reported elevated antibodies to HIV p24 core antigen, stabilized CD4 counts in some cohorts, and no serious adverse events beyond injection-site reactions.[55][54] At the 1993 International AIDS Conference, Salk presented data suggesting reduced viral burden and delayed progression, though experts expressed skepticism due to small sample sizes and lack of placebo controls, noting HIV's antigenic variability complicated broad efficacy.[55] By 1995, an FDA advisory panel endorsed Phase III trials for Remune in up to 5,000 patients, citing preliminary immune boosts despite inconclusive survival data.[56] Salk's death on June 23, 1995, preceded full outcomes; subsequent IRC-led Phase III studies, enrolling over 2,500 participants by 1999, failed primary endpoints of preventing AIDS onset or death, with no statistically significant differences versus controls.[57] IRC contested analyses showing null results, alleging mishandling of surrogate markers like CD4 levels, and pursued legal action against publications, but regulatory scrutiny and trial failures halted further development, underscoring HIV's causal complexities—such as latent reservoirs and mutation rates—that resisted Salk's inactivated model.[58][59] These efforts, while innovative in emphasizing therapeutic intervention, highlighted empirical limits: unlike polio's extracellular lifecycle, HIV's intracellular persistence demanded novel strategies beyond whole-virus inactivation.[17][18]Biophilosophy and Evolutionary Thought
Salk developed the concept of biophilosophy as the integration of biological and evolutionary principles into analyses of philosophical, cultural, social, and psychological issues, aiming to foster a holistic understanding of human development and societal challenges.[60] This framework sought to bridge scientific inquiry with humanistic perspectives, viewing biology not merely as a descriptive science but as a lens for anticipating and shaping human potential.[61] In his vision, biophilosophy extended beyond empirical virology to explore how evolutionary processes inform ethical and existential questions, emphasizing conscious adaptation in an era of rapid technological change.[62] Central to Salk's evolutionary thought was the idea that humanity represents an ongoing stage in cosmic evolution, unfolding through stages from inorganic matter to organic life, symbolic ideas, technology, and ultimately integrative wisdom.[63] He posited that ideas themselves evolve akin to biological entities, subject to selection pressures that favor adaptive concepts for survival and progress.[64] In Man Unfolding (1972), Salk argued that human evolution involves deliberate experimentation with environmental challenges, revealing latent potentials through rational and intuitive faculties, rather than passive adaptation alone.[65] This work framed evolution as a purposeful process, where individuals and societies must actively "unfold" to align with biological imperatives. Salk's The Survival of the Wisest (1973) extended these ideas into metabiology—a philosophical extension of biology—contending that wisdom, defined as balanced judgment integrating intuition and reason, becomes the key selective force in post-Darwinian human evolution.[66] He suggested that metabolic and environmental stresses, including overpopulation, impose evolutionary pressures favoring wiser adaptations over mere physical fitness, urging societies to prioritize intellectual and ethical maturation for long-term viability.[67] Later, in Anatomy of Reality: Merging of Intuition and Reason (1983) and collaborative works like World Population and Human Values: A New Reality (1981) with his son Jonathan, Salk applied evolutionary realism to contemporary issues, linking reduced societal problems—such as resource strain—with decelerating population growth and value shifts toward sustainability.[18] These writings critiqued unguided progress, advocating question-driven evolution where solutions emerge from aligning human behavior with biological causality.[68]Personal and Professional Endgame
Family Dynamics and Relationships
Jonas Salk was born on October 28, 1914, in New York City as the eldest of three sons to Daniel B. Salk and Dora (née Press) Salk, Russian-Jewish immigrants who emphasized education despite their own lack of formal schooling.[1][7] His father worked in the garment industry, while his mother managed the household; the family's modest circumstances instilled a drive for intellectual achievement, with Salk's parents prioritizing their sons' academic success amid the challenges of immigrant life.[69] His younger brothers were Herman and Lee, the latter of whom pursued a career as a child psychologist.[70] In 1939, shortly after earning his medical degree from New York University, Salk married Donna Lindsay, a Smith College graduate and social worker pursuing a master's in social work.[71] The couple had three sons: Peter (born 1941), Darrell, and Jonathan, all of whom later entered medical fields—Peter as an infectious disease specialist, Darrell as a pediatric geneticist, and Jonathan as a psychiatrist.[72][73] In 1953, Salk tested an early version of his inactivated polio vaccine on his sons, starting with Peter and Darrell, who showed no adverse effects, a decision rooted in his confidence in the vaccine's safety derived from prior animal and small-scale human trials.[74] The marriage endured until 1968 but was strained by Salk's intense career demands and rising fame following the 1955 polio vaccine announcement, which biographer Charlotte DeCroes Jacobs attributes to Donna's inability to adapt to the ensuing public scrutiny and social isolation.[75] Jacobs further documents Salk's extramarital affairs during this period, contributing to marital discord.[76] Salk's second marriage, to artist Françoise Gilot on June 29, 1970, in Neuilly-sur-Seine, France, proved more enduring, lasting until his death in 1995; Gilot, previously known for her relationship with Pablo Picasso and as mother to his children Claude and Paloma, brought artistic perspectives that complemented Salk's scientific pursuits, with the couple dividing time between California and Paris.[77] No children resulted from this union, but it provided Salk personal stability amid his later research endeavors, contrasting the familial tensions of his first marriage.[78] His sons maintained involvement in his legacy, including donating materials to institutions like the University of Pittsburgh in 2023 to honor his polio work.[79]Final Years, Health Decline, and Death
In his final years, Jonas Salk remained actively involved with the Salk Institute for Biological Studies in La Jolla, California, where he directed research efforts toward developing a therapeutic vaccine against HIV. This work aimed to stimulate immune responses in infected individuals to delay the progression to AIDS, building on preclinical studies that showed promise in enhancing T-cell activity against the virus. Salk published findings from these initiatives, including a 1987 paper detailing an inactivated HIV vaccine candidate tested in chimpanzees, though human trials faced regulatory hurdles and did not advance to widespread use.00407-5/fulltext)[7] Salk's health appeared robust enough to sustain his scientific pursuits into his late seventies, with no publicly documented chronic conditions dominating his later biography prior to his sudden passing. On June 23, 1995, he suffered fatal heart failure at his home in La Jolla at the age of 80. The Salk Institute confirmed the cause as cardiac arrest, attributing it to natural age-related decline rather than any specified prior illness.[71][1]Enduring Impact and Debates
Public Health Achievements and Data
The inactivated poliovirus vaccine (IPV) developed by Jonas Salk represented a pivotal advancement in preventing paralytic poliomyelitis, a disease that had paralyzed tens of thousands annually in the United States during the early 1950s. Salk's formulation used formalin-killed virus strains grown in monkey kidney cells, tested initially on himself, his family, laboratory staff, and institutionalized children in 1953 before large-scale evaluation.[2][18] In 1954, a double-blind field trial involving approximately 1.8 million children across the United States, Canada, and Finland demonstrated the vaccine's efficacy, reducing paralytic polio incidence by 80-90% compared to placebo controls, with results announced on April 12, 1955, as safe, potent, and effective.[80][3] Mass immunization campaigns followed, contributing to a sharp decline in U.S. cases; for instance, reported paralytic cases fell from over 21,000 in 1952 to 2,525 by 1960 and just 61 by 1965.[81]| Year | Reported Paralytic Polio Cases in the U.S. |
|---|---|
| 1952 | >21,000 |
| 1960 | 2,525 |
| 1965 | 61 |
